United States, Feb. 25 -- GE HealthCare has delivered the first patient doses of Flyrcado (TM) (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for the detection of coronary artery disease (CAD), at early adopter imaging centers in the US. This milestone follows the recent FDA approval of Flyrcado, which is indicated for patients with known or suspected CAD, and delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI, the predominant procedure used in nuclear cardiology today. This month, Houston Methodist Hospital delivered the first doses in a phased rollout of the cardiac PET agent at early adopter imaging c...